It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Axin1 is a negative regulator of β-catenin signaling and its role in osteoblast precursor cells remains undefined. In the present studies, we determined changes in postnatal bone growth by deletion of Axin1 in osteoblast precursor cells and analyzed bone growth in newborn and postnatal Axin1Osx mice and found that hypertrophic cartilage area was largely expanded in Axin1Osx KO mice. A larger number of chondrocytes and unabsorbed cartilage matrix were found in the bone marrow cavity of Axin1Osx KO mice. Osteoclast formation in metaphyseal and subchondral bone areas was significantly decreased, demonstrated by decreased TRAP-positive cell numbers, associated with reduction of MMP9- and cathepsin K-positive cell numbers in Axin1Osx KO mice. OPG expression and the ratio of Opg to Rankl were significantly increased in osteoblasts of Axin1Osx KO mice. Osteoclast formation in primary bone marrow derived microphage (BMM) cells was significantly decreased when BMM cells were cultured with conditioned media (CM) collected from osteoblasts derived from Axin1Osx mice compared with BMM cells cultured with CM derived from WT mice. Thus, the loss of Axin1 in osteoblast precursor cells caused increased OPG and the decrease in osteoclast formation, leading to delayed bone growth in postnatal Axin1Osx KO mice.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details


1 Shanghai University of Traditional Chinese Medicine, Longhua Hospital, Shanghai, China (GRID:grid.412540.6) (ISNI:0000 0001 2372 7462); Shanghai Academy of Traditional Chinese Medicine, Spine Institute, Shanghai, China (GRID:grid.412540.6) (ISNI:0000 0001 2372 7462); Key Laboratory, Ministry of Education of China, Shanghai, China (GRID:grid.419897.a) (ISNI:0000 0004 0369 313X)
2 Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Research Center for Human Tissues and Organs Degeneration, Shenzhen, China (GRID:grid.458489.c) (ISNI:0000 0001 0483 7922)
3 Rush University Medical Center, Department of Orthopedic Surgery, Chicago, USA (GRID:grid.240684.c) (ISNI:0000 0001 0705 3621)
4 Shanghai University of Traditional Chinese Medicine, Longhua Hospital, Shanghai, China (GRID:grid.412540.6) (ISNI:0000 0001 2372 7462); Key Laboratory, Ministry of Education of China, Shanghai, China (GRID:grid.419897.a) (ISNI:0000 0004 0369 313X)
5 Southern University of Science and Technology, School of Medicine, Shenzhen, China (GRID:grid.263817.9)